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Abstract
Although a combination of genomic and epigenetic alterations are implicated in the multistep transformation of normal
squamous esophageal epithelium to Barrett esophagus, dysplasia, and adenocarcinoma, the combinatorial effect of these changes
is unknown. By integrating genome-wide DNA methylation, copy number, and transcriptomic datasets obtained from endoscopic
biopsies of neoplastic progression within the same individual, we are uniquely able to define the molecular events associated
progression of Barrett esophagus. We find that the previously reported global hypomethylation phenomenon in cancer has its
origins at the earliest stages of epithelial carcinogenesis. Promoter hypomethylation synergizes with gene amplification and leads
to significant upregulation of a chr4q21 chemokine cluster and other transcripts during Barrett neoplasia. In contrast, gene-specific
hypermethylation is observed at a restricted number of loci and, in combination with hemi-allelic deletions, leads to
downregulatation of selected transcripts during multistep progression. We also observe that epigenetic regulation during
epithelial carcinogenesis is not restricted to traditionally defined ‘‘CpG islands,’’ but may also occur through a mechanism of
differential methylation outside of these regions. Finally, validation of novel upreg u l a t e dt a r g e t s( C X C L 1a n d3 ,G A T A 6 ,a n d
DMBT1) in a larger independent panel of samples confirms the utility of integrative analysis in cancer biomarker discovery.
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Introduction
Theincidenceofesophageal adenocarcinoma(EAC)is increasing
at an alarming pace in the United States (.600% increase since
1975) [1]. Since most patients with EAC present at diagnosis with
an advanced disease stage, the 5-year survival rate is a dismal 13%
[2], underscoring the pressing need for early diagnostic biomarkers,
as well as for improved therapeutic strategies, in this malignancy.
Distinct pathological stages of specialized columnar epithelium
(Barrett metaplasia) and low- followed by high-grade dysplasia
precede adenocarcinoma [3,4]. Barrett esophagus (BE) is defined as
a change in the esophageal epithelium that can be recognized
grossly by a distinct salmon pink color at endoscopy, and confirmed
by the presence of specialized columnar epithelium on biopsy. The
prevalence of BE is not preciselyknown,butithasbeen estimated to
range between 1–10% of the general population [5]. The incidence
of EAC in patients with BE is increased 100-fold above that of the
general population [6]. Thus, BE, with or without associated
epithelial dysplasia, provides a unique opportunity for risk
stratification and secondary prevention of EAC.
Expression profiling of BE and EAC using genome-wide
approaches has identified many of the transcriptomic alterations
PLoS Genetics | www.plosgenetics.org 1 March 2011 | Volume 7 | Issue 3 | e1001356occurring during esophageal neoplastic progression [7-10]. In
several instances, it has also been possible to identify the proximate
genomic or epigenetic mechanism (for example, intragenic
deletion, truncating mutation, copy number aberration, or
promoter methylation, respectively) contributing to the altered
expression [11-16]. This strategy has unequivocally yielded a rich
seedbed of candidate biomarkers for diagnosis, as well as for
prognostication, of BE neoplasia [17-20]. Nonetheless, there
remains a notable lacuna in globally integrating transcriptomic
abnormalities during Barrett progression with the corresponding
changes occurring at the level of the genome and epigenome. We
reasoned that a multi-platform integrated approach would not
only enable the elucidation of novel biomarkers, but also clarify
the genomic and/or epigenetic mechanisms driving transcript
abnormalities during carcinogenesis. Such integration of global
datasets has begun to emerge in solid tumors [21,22], but to the
best of our knowledge this has not been performed in precursor
lesions, especially in the context of multistep progression occurring
in a single individual. Herein, we provide an unbiased and
comprehensive approach for integrating large-scale genomic,
epigenetic, and transcriptomic datasets, obtained using tissue from
patients undergoing endoscopic mucosal biopsy for BE. In contrast
to numerous prior studies using two platforms (for example,
combined copy number and expression analysis) where a ‘‘hit’’ on
the second allele is typically inferred, the multi-platform analysis
performed here can directly confirm or refute the Knudsonian
paradigm for a given altered transcript. Our studies have identified
striking epigenomic alterations, and in specific, widespread
hypomethylation, which occurs at the earliest stages of epithelial
carcinogenesis. This approach is in direct contrast to most single-
or limited-locus studies that have focused on epigenetic silencing of
candidate tumor suppressor genes by hypermethylation of the
promoter. In addition, we have identified clustered transcripts,
such as the chemokine ligands CXCL1 and 3, that are markedly
upregulated via simultaneous biallelic alteration by hypomethyla-
tion and gene amplification, respectively, and whose protein
products have the potential to serve as serum biomarkers of
neoplastic progression in BE.
Results
Widespread hypomethylation is an early event in the
progression of Barrett esophagus
Eight histologically validated endoscopic mucosal biopsies
representing normal squamous mucosa and the various histopath-
ological stages of Barrett esophagus progression were obtained
from three patients undergoing repeat endoscopy for dysplasia
(Figure 1A, Figure S1); two additional unmatched gastric cardia
biopsies were obtained as controls for the intended profiling
studies. Prospective as well as retrospective surveillance studies
have convincingly established that nondysplastic BE and low-
grade dysplasia (LGD) both have a significantly lower risk of
progression to EAC, when compared to high-grade dysplasia
(HGD); in fact, for the purposes of therapeutic decision-making
between continued surveillance versus local ablation, stratification
typically occurs based on the diagnosis of HGD in BE mucosa.
Therefore, with the objective of pair-wise comparison, samples of
non-dysplastic BE and LGD were categorized as ‘‘low’’, while the
two HGD samples and one EAC were categorized as ‘‘high’’.
Nucleic acids extracted from cryostat-embedded sections of the ten
samples were utilized for three concurrent microarray-based
assays: 1) gene expression profiling, 2) array comparative genomic
hybridization (aCGH), and 3) genome-wide cytosine methylation,
thus simultaneously querying the transcriptome, genome, and
epigenome, respectively. Methylation profiling was performed
using the HpaII tiny fragment Enrichment by Ligation-mediated
PCR (HELP) assay, which compares HpaII (methylation-sensitive)
and MspI (methylation insensitive) genomic representations to
identify hypo- and hypermethylated loci in the genome.[23-25].
The HELP HpaII / MspI ratios were validated at over 60
independent loci by mass spectrometry-based high-throughput
quantitative methylation PCR analysis (Sequenom EpiTYPER);
based on this quantitative approach, a HpaII/MspI ratio of 0.3
corresponded to 50% cytosine methylation (Figure S2) and was
used as a threshold for defining hypo- or hypermethylation.
Unsupervised hierarchical clustering analyses demonstrated
that, at the level of the transcriptome, squamous mucosa clustered
discretely from ‘‘glandular’’ epithelium (including gastric cardiac
as well as all stages of BE progression: Figure 1B); in contrast, at
the level of the epigenome, ‘‘normal’’ mucosa (including both
squamous and cardiac subtypes) clustered discretely from all
‘‘abnormal’’ (i.e., BE) epithelia (Figure 1C). These results suggest
some degree of commonality of epigenetic profiles between
otherwise normal gastrointestinal tissues, despite obvious morpho-
logical differences. A pair-wise comparison of transcriptomic
profiles between normal esophageal squamous and gastric cardiac
mucosal samples revealed large numbers of significantly differen-
tially expressed transcripts, consistent with the distinct histogenesis
and biologies of these normal mucosal subtypes (Figure 1D, left); in
contrast, global cytosine methylation profiles between the two
mucosal locations were considerably more overlapping, with
significant differences in either hypo- or hypermethylation
restricted to fewer loci (Figure 1E, left).
In pair-wise comparisons of gene expression during BE
progression, we found large numbers of significantly differentially
expressed transcripts between the early lesions of Barrett
metaplasia and LGD (both classified as ‘‘Low’’) versus normal
squamous mucosa, confirming the previous observation [7] that
even non-dysplastic Barrett epithelium may harbor profound
transcriptomic aberrations, some comparable to EAC (Figure 1D,
middle). Significant gene expression differences between ‘‘high and
‘‘low’’ BE lesions were more attenuated and restricted to only
a handful of loci (Figure 1D, right). While these gene expression
Author Summary
The incidence of esophageal adenocarcinoma (EA) is
increasing at an alarming pace in the United States. Distinct
pathological stages of Barrett’s metaplasia and low- and
high-grade dysplasia can be seen preceding malignant
transformation. These precursor lesions provide a unique in
vivomodelfordeepeningourunderstanding the earlysteps
in human neoplasia. By integrating genome-wide DNA
methylation, copy number, and transcriptomic datasets
obtained from endoscopic biopsies of neoplastic progres-
sion within the same individual, we are uniquely able to
define the molecular events associated progression of
Barrett esophagus. We show that the predominant change
during this process is loss of DNA methylation. We show
that this global hypomethylation occurs very early during
the process and is seen even in preinvasive lesions. This loss
of DNA methylation drives carcinogenesis by cooperating
with gene amplifications in upregulating proteins during
this process. Finally we uncovered proteins that upregu-
lated by loss of methylation or gene amplification (CXCL1
and 3, GATA6, and DMBT1) and show their relevance by
validating their levels in larger independent panel of
samples, thus confirming the utility of integrative analysis
in cancer biomarker discovery.
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revealed an unexpected dimension to epigenetic dysregulation
during BE progression. Contrary to the hypermethylation
reported in previous single-locus studies, we identified significant
hypomethylation occurring at a large number of loci genome-wide
during the transition of squamous mucosa to Barrett epithelium
(1160 hypomethylated versus 114 hypermethylated loci., Figure 1E,
middle,); since this epigenetic ‘‘shift’’ is not observed in the
comparison of normal esophageal squamous versus cardiac mucosal
samples, we believe these methylation alterations may be reflective
Figure 1. Global hypomethylation is seen early during esophageal carcinogenesis. Multiple endoscopic biopsies collected at the same
time from patients with clinical history of Barrett’s esophagus, were classified as normal squamous epithelium, Barrett’s metaplasia, low grade
dysplasia (LGD), high grade dysplasia (HGD) and adenocracinoma based on histology. (Panel A). Frozen tissue samples were homogenized, used for
DNA and RNA isolation and were subjected to global expression profiling, DNA methylation profiling and DNA copy number analysis. Unsupervised
hierarchical clustering based on gene expression profiling shows clustering of distinct histologic tissues with glandular tissue from stomach cardia
being more similar to metaplastic and dysplastic tissues (Panel B). Clustering based on methylation shows dissimilarity between normal (esophageal
and stomach) and abnormal tissues (Panel C). Volcano plots demonstrating significance and magnitude of change in mean gene expression (Panel D)
and DNA methylation (Panel E) are shown. Each plot represents either 36,847 genes from the microarray experiment (D) or 25,626 HpaII-amplifiable
fragments (HAF) from the HELP assay (E). The log2 ratio of difference of means is shown on the x-axis and the negative log of the p-value (based on
paired T-Test) is shown on the y-axis. Genes that are significantly downregulated (panel D) or hypermethylated (panel E) are shown in green and red
dots indicate genes that are either upregulated (panel D) or hypomethylated (panel E). Global methylation is shown by density plots of log2 of HpaII/
MspI ratios and shows bimodal distribution in normal epithelial tissues with both hypo and hypermethylated loci. The red line denotes the median
HpaII/MspI ratio for random probes. A shift towards hypomethylation is observed during transformation of normal to low grade dysplasia in
a representative series of samples (Panel F). Quantitative methylation for matched pairs of normal and Barrett’s dysplasia as done by the LUMA assay.
X axis shows mean percent hypomethylation of 3 independent paired samples. (Panel G).
doi:10.1371/journal.pgen.1001356.g001
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acquisition of columnar histology. A second, smaller wave of
hypomethylation was observed when comparing ‘‘high’’ versus
‘‘low’’ BE categories (Figure 1E, right). This progressive hypo-
methylation was seen in methylation profiles of samples from the
same patients (Figure 1F). Validation at the whole-genome level by
the Luminometric methylation assay (LUMA) revealed a signifi-
cantly large increase in unmethylated CpGs in ‘‘low’’ BE samples
versus matched normal squamous mucosa (Figure 1G). These
results demonstrate that the previously reported global hypo-
methylation observed in human cancers [26] can initiate at a very
early stage of neoplastic transformation, such as in the non-
invasive precursors of EAC.
Differential methylation within gene promoters is not
restricted to CpG islands but also involves CG
dinucleotides outside of these islands
In addition to this panoramic view of epigenetic shifts, we also
assessed the nature of the HpaII sites showing altered methylation
during BE progression. As our microarray design includes both
canonical CpG islands and additional CG dinucleotide loci within
gene promoters, we sought to test whether CpG islands, long
considered the principal target of epigenetic dysregulation in
cancer [27], were disproportionately affected. We compared the
proportions of loci at which differential methylation was occurring
within CpG islands versus other CG dinucleotide loci represented
on the microarray. We determined that the majority of HpaII loci
exhibiting differential methylation during BE progression lay,
paradoxically, outside of canonical CpG islands (Figure 2A). To
further validate this observation at a representative locus, we chose
the example of Deleted in Malignant Brain Tumor 1 (DMBT1), whose
gene promoter lacks a defined CpG island, yet demonstrates
progressive hypomethylation accompanied by significant tran-
script upregulation during BE progression (Figure 2B). Histological
examination of DMBT1 protein expression in a large archival
cohort of 120 BE samples and 54 normal controls revealed
significant (P,0.05) upregulation of this protein early during BE
neoplasia (Figure 2C, 2D), thus validating the results obtained
from our array-based analysis. These results suggest an epigenetic
regulatory function for CG dinucleotide elements in the genome
that do not meet the threshold for canonical CpG islands, which
are strictly defined on base compositional criteria [28].
Integrated multi-platform analysis provides experimental
evidence of silencing of tumor suppressor genes by both
genetic and epigenetic mechanisms in concordance with
Knudson’s two hit hypothesis
Subsequently, in order to generate a multi-component genetic
model of BE progression, we developed an in silico algorithm for
integrating data from these three high-resolution platforms (i.e.,
gene expression, HELP, and aCGH), using genomic coordinates
for the respective probes from each of the platform arrays
(Figure 3A). This algorithm, which we call Multi-dimensional
Integration of Genomic data from Human Tissues (MIGHT),
provides a composite three-dimensional graphical output of gene
sets demonstrating significant alterations in pair-wise unbiased
comparisons across the different array platforms (Figure 3B, 3C).
By integrating differences in transcript expression with both
methylation status and copy number at a given locus, the MIGHT
algorithm not only identifies significant transcriptomic alterations
during neoplastic progression, but also elucidates the relative
contributions of genomic and epigenetic factors toward such
deregulation. The advantage of an integrative approach in
developing an accurate ‘‘patient-specific’’ multi-component genet-
ic progression model is illustrated in Figure 4. A chromosome
9p21 hemizygous deletion was identified by aCGH analysis of
LGD and HGD biopsies obtained from this individual, which was
absent in the matched normal esophageal squamous epithelium,
consistent with a somatic monoallelic loss, as confirmed by FISH
analysis (Figure 4B). This region harbors two closely approximated
tumor suppressor genes: CDKN2A/p16 and CDKN2B/p15. Prior
copy number and other studies have implicated CDKN2A as the
target of inactivation at this locus in BE [15,17,29] Nevertheless, in
this particular example, microarray data demonstrated that the
relative fold reduction in gene expression was considerably greater
for CDKN2B (,100-fold downregulation) than for CDKN2A (,4-
fold); moreover, this finding was independently validated by qRT-
PCR, which confirmed the complete absence of CDKN2B
transcripts in the dysplastic biopsy samples, while the expression
of CDKN2A, albeit significantly reduced, was still detectable.
Analysis of the third component (HELP analysis) clarified that the
CDKN2B promoter in the retained allele underwent progressive
hypermethylation during BE progression, while the CDKN2A
promoter maintained its methylation status quo (Figure 4A, bottom).
This finding suggests the importance of methylation of the
remaining allele in regulating expression, and provides direct
experimental evidence for genetic and epigenetic hits acting
concurrently and synergistically to downregulate tumor suppressor
genes during oncogenesis through bi-allelic inactivation (Figure
S3).
Integrated multi-platform analysis as a tool for biomarker
discovery in multistep carcinogenesis
Finally, in addition to the value of integrated datasets in
understanding mechanisms of transcript disruption (as illustrated
above), we explored the utility of the MIGHT algorithm as a tool
for biomarker discovery in Barrett progression. In particular, we
focused on genes that were significantly overexpressed in pair-wise
comparisons, by hypomethylation and / or genomic amplification,
and validated selected examples of patient-specific aberrations in
larger sample sets.
Using the MIGHT platform, we determined that many genes
not previously implicated in esophageal carcinogenesis were
significantly upregulated during stepwise progression to cancer
(Figure 2 and Tables S1, S2, S3, S4). These were upregulated by
either loss of methylation, or gene amplification, or both occurring
together. Genes previously known to be important during
metaplastic transformation of squamous to columnar epithelium
were also included in the list of most significantly upregulated
transcripts (for example, villin and mucin genes), confirming the
biological validity of our assays. Transcripts corresponding to
a family of chemokine ligands were among the most significantly
upregulated, and the corresponding gene cluster is present on the
4q21 chromosomal segment that was amplified in all patient
samples during the process of Barrett neoplasia (Figure 5A, 5B)
Integrative analysis revealed that in addition to amplification, the
CXCL1 and CXCL3 gene promoters were also hypomethylated
during transformation, and their relative increase in transcript
expression was many fold greater (4–6 fold by array, 10–20 fold by
qRT-PCR) than that of IL-8, a chemokine gene which was part of
the 4q21 amplicon but whose promoter was not affected by loss of
methylation (Figure 5A, Bottom). These observations were
validated by qRT-PCR in larger independent set of primary
samples (Figure 5C), and confirmed a greater than 30-fold mean
increase in CXCL1 and CXCL3 levels when compared to IL-8
transcripts at each histological grade of BE progression, thus
demonstrating the combinatorial affect of both genetic and
Hypomethylation during Esophageal Carcinogenesis
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carcinogenesis.
In light of the significant upregulation of chromosome 4q21
chemokine cluster transcripts in BE and EAC, and the likely
secretion of their protein products into the circulation, we
evaluated the potential of using this chemokine familyas serum
biomarkers of EAC. Serum samples were collected from an
independent cohort of patients with EAC and were compared to
samples from patients with gastroesophageal reflux disease
(GERD) symptoms without demonstrable BE on histology. Levels
of chemokine ligands, IL-8 (IL8), IP-10 (CXCL10), Eotaxin
(CCL11), MCP-1 (CCL2) and MCP-4 (CCL13) were determined
in serum samples by a multiplexed assay on an ultra-sensitive
chemiluminiscence detection platform. We observed that both
chemokines that were a part of the amplified 4q21 segment (IL-8
and CXCL10) were significantly elevated in the EAC serum
samples compared to the controls(P,0.05), while none of
chemokines outside of this amplicon demonstrated a significant
difference between cancer and control specimens (Figure 5D).
These results validate the feasibility of identifying candidate
biomarkers by integrative analysis in a limited number of patient
samples, and extrapolating their utilization to larger, independent
patient cohorts.
To further functionally validate the utility of our integrative
discovery platform, we focused on a transcription factor, GATA6,
which was significantly overexpressed early in Barrett metaplasia,
and was predicted by MIGHT to be amplified without
concomitant alterations in methylation (Figure 3). Assessment of
the aCGH data and FISH on primary tissues readily validated the
copy number alterations at the GATA6 locus during esophageal
carcinogenesis (Figure 6A, 6B). Thereafter, using independent
cohorts of snap-frozen and archival BE samples, respectively, we
observed significant upregulation of GATA6 transcript expression
(.500 fold mean increase in LGD, HGD and EAC samples,
Figure 6C, 6D) and of the Gata6 protein levels (No Gata6 staining
observed in 54 normal controls when compared to mean 60%
positivity in a total of 201 LGD, HGD and EAC samples;
Figure 6F–6I), confirming the results from the genomic analysis.
To validate an oncogenic role in esophageal carcinogenesis, we
used an esophageal adenocarcinoma-derived cell line, OE33 [30]
and observed significant overexpression of Gata6 protein in these
cells (Figure 6J). GATA6 was successfully knocked down using
lentiviral short hairpin RNAs in OE33 cells (Figure 6K). Loss of
Gata6 function did not affect proliferation, (Figure 6L) but resulted
in significantly decreased anchorage independent growth of OE33
cells and also led to decrease in invasion and migration
(Figure 6M–6P), thus providing a putative functional association
between GATA6 amplification and disease progression in BE.
Discussion
Esophageal cancer is the cancer with the fastest-growing
prevalence in the United States [1] and arises from the metaplastic
transformation of normal squamous mucosa, through the
intermediate stages of dysplasia, culminating in cancer. Newer
insights into the pathogenesis of this process are critically needed
for prevention and early diagnosis of these lesions. Although
alterations in DNA methylation have been described during
esophageal carcinogenesis, studies performed thus far have focused
on the aberrant hypermethylation of CpG islands located within
promoters of selected tumor suppressors such as CDKN2A/p16,
HPP, RUNX3, REPRIMO, amongst others. In contrast, we have
Figure 3. Global integrative analysis of transcriptomic, epigenomic, and DNA copy number data. Probes from all three arrays were
linked to genes on the basis of genomic coordinates isolated from NCBI build35. Pairwise analysis was performed between main histologic groups of
normal squamous vs LOW (B) and LOW vs HIGH (C). The x axis represents fold-change differences (log2) in gene expression, the y axis represents fold-
change differences (log2) in methylation and the z axis represents the significance of these changes (–log10 p-value) for both platforms. Upregulated
genes (.2.5 fold change in GE with a p-value,0.05) are shown in green and downregulated genes are shown in red. Darker shading of these colors is
used to represent genes that are significantly differentially methylated. Hypermethylated genes are at the top of the graph and hypomethylated
genes on the bottom. Finally, copy number changes are defined by ‘‘volume’’. Genes with copy number changes (amplified or deleted) are depicted
by larger sized circles. This plot allows us to visualize differentially regulated genes and the mechanisms of their dysregulation.
doi:10.1371/journal.pgen.1001356.g003
Figure 2. DMBT1 upregulation by non-CpG island methylation changes. Differentially methylated loci between normal esophageal
epithelium and Barretts/LGD were mapped to genomic locations of CpG islands. A large percentage of these loci were not within CpG islands. Paired
T Test was used to compare to distribution of loci present on the HELP array (A). The DMBT1 gene is not amplified (panel B) and lacks a CpG island in
its promoter. DMBT1 was seen to be significantly upregulated and hypomethylated during integrative analysis and marked upregulation was
validated by qRT-PCR (red bar). Significant hypomethylation was seen by the HELP assay (green bar) and validated by quantitative MassArray (B).
Immunohistochemical evaluation of the protein levels of the DMBT1 gene on primary tissues shows a frequent and significant protein upregulation
during early stage dysplasia (panel C,D).
doi:10.1371/journal.pgen.1001356.g002
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PLoS Genetics | www.plosgenetics.org 6 March 2011 | Volume 7 | Issue 3 | e1001356Figure 4. Differential inactivation of the CDKN2A/CDKN2B locus by combination of genomic and epigenetic mechanisms. In an index
patient with serial progression biopsies, there is a hemizygous deletion of the CDKN2A/CDKN2B gene locus at 9p21, beginning at the stage of LGD,
and persisting into the corresponding HGD sample (Panel A), which is accompanied by expected downregulation of both transcripts in expression
microarray data. Although independent qRT-PCR for CDKN2A and CDKN2B transcripts (red bars) validates the expression array data (blue bars), the
magnitude of downregulation of CDKN2B is more pronounced than CDKN2A (,100-fold versus ,5-fold on microarray, and complete absence of
CDKNA2B transcripts on qRT-PCR versus downregulated but detectable CDKN2A transcripts). MIGHT analysis confirms that this discrepancy between
closely spaced hemizygously deleted loci correlates with increased promoter methylation of the residual CDKNA2B allele, as demonstrated by the
HELP assay (green bars); such progressive hypomethylation is not observed on the residual CDKN2A allele and likely is responsible for the reduced but
demonstrable transcripts. Uniallelic deletion of the CDKN2A/CDKN2B locus is validated by FISH (Panel B) on primary tissue as shown by loss on the LSI
p16 SpectrumOrange probe (red arrows).
doi:10.1371/journal.pgen.1001356.g004
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is the more pervasive epigenetic alteration that occurs during
Barrett progression. Additionally, we determined that global
cytosine hypomethylation occurs very early during multistep
carcinogenesis, observed within the first discernible metaplastic
lesions within the native squamous esophagus. Even though global
hypomethylation was reported in the pioneering epigenetic studies
in cancer [31], most investigators have subsequently focused on
hypermethylation in CpG islands within selected gene promoters.
Hypomethylation has been hypothesized to lead to carcinogenesis
by encouraging genomic instability [32] as well as by aberrant
activation of oncogenes [33]. Additionally, as illustrated in the
Figure 5. Aberrant expression of a 4q21 chemokine cluster by gene amplification and promoter hypomethylation during
esophageal carcinogenesis. In an index patient with serial progression biopsies, amplification of chromosome 4q21, containing a cluster of genes
transcribing chemokine ligands, is seen beginning at LGD, and persisting into HGD (Panel A). Expression and promoter methylation data for three
representative genes in this amplicon (CXCL1, CXCL3, and IL8) are shown below the copy number window. All three transcripts are upregulated in the
LGD and HGD samples by microarray data (blue bars), which is validated using independent qRT-PCR assays (red bars). Nonetheless, there is strikingly
higher upregulation of CXCL1 (.200-fold on qRT-PCR compared to matched normal) and CXCL3 (500–700 fold on qRT-PCR compared to normal),
versus the 10–30 fold upregulation in IL8 mRNA. Integrative analysis on the MIGHT platform confirms that this is likely arises due to progressive
hypomethylation of the CXCL1 and CXCL3 promoters (as gauged by HELP assay, green bars), which is not seen at the IL8 promoter. The
hypomethylation of CXCL1 observed in the dysplastic samples by the HELP assay is validated by Mass Array at the bottom. The 4q21 chemokine
cluster amplification is also confirmed by FISH (Panel B) on the corresponding archival HGD sample from the same individual used in the integrative
analysis. The RP11-94K4 SpectrumOrange probe representing the 4q21.1 - 4q21.2 amplicon (red arrows) was used. Moreover, the upregulation of IL8,
CXCL1, and CXCL3 transcripts is also confirmed in an independent panel of endoscopic mucosal biopsy samples, including LGD (N=5), HGD (N=5),
and adenocarcinoma (N=3) (Panel C). Notably, the significantly greater upregulation of CXCL1 and CXCL3 transcripts observed in the index patient
persists in this independent cohort of cases. Finally, chemokine detection using a multiplex chemiluminiscent assay was performed on five serum
samples from patients with esophageal adenocarcinoma (designated ‘‘Cancer’’) and compared to samples from controls with GERD symptoms and
normal esophageal histology (designated ‘‘Normal’’) (Panel D). Serum levels of only two chemokines, IL-8 and CXCL-10, both encoded by the 4q21
cluster, are significantly higher in cancer patients when compared to normals, supporting the evidence that members encoded by this amplicon are
expressed at higher levels when compared to chemokines that are not part of the amplicon, such as CCL2, CCL11 and CCL13. Unfortunately, CXCL1
and CXCL3 were not included in this pre-formed multiplex assay.
doi:10.1371/journal.pgen.1001356.g005
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PLoS Genetics | www.plosgenetics.org 9 March 2011 | Volume 7 | Issue 3 | e1001356example of DMBT1, hypomethylation alone can lead to
transcriptional upregulation during multistep progression to
high-grade dysplasia and cancer. Furthermore, our data identify
CG dinucelotide loci that can be targeted by differential
methylation during neoplastic progression and are located outside
of canonical CpG islands. Importantly, these CG alterations are
not merely stochastic in nature, but appear to have bona fide
regulatory influence on transcript expression. Recent work has
similarly shown that cytosines present outside of CpG islands can
be aberrantly methylated/ hypomethylated in cancer, and assays
that cover these loci are critical to discovering the full landscape of
altered methylome of malignancies [34,35].
Since carcinogenesis is multifactorial and gene inactivation and
activation can be influenced by either genetic or epigenetic
mechanisms, we performed an integrative analysis to dissect the
relative contributions of these alterations during this process. Our
study provides direct experimental evidence of deletions and
promoter methylation acting in concert to silence tumor
suppressors in a bi-allelic manner, as first postulated by
Knudson’s two-hit paradigm. We expand on this paradigm by
demonstrating that gene amplifications and hypomethylation can
function in concert to upregulate gene expression of various
genes. Of note, the use of an integrated approach facilitated by
the MIGHT algorithm provides accurate in silico insights into
mechanisms of deregulation, particularly when closely spaced
gene clusters harbor discrepant alterations in transcript level, as
exemplified by CDKN2A and CDKN2B, or the chemokine family
in the 4q21 amplicon. In each of these instances, a subsequent
validation step (such as FISH analysis for deletion, or MassArray
for promoter methylation, respectively) confirmed the suggested
mechanism of transcript deregulation implicated by MIGHT,
underscoring the robustness of the analysis platform. Finally, we
demonstrate that multiplatform high resolution integrative
analysis of limited number of well annotated samples (N =
three patients) can lead to findings that can be extrapolated to
larger independent sample cohorts. We have illustrated this
paradigm using multiple examples throughout the text, such as
with the 4q21 chemokine cluster, DMBT1, and GATA6. In each
of these examples, we validated the findings elucidated in the
‘‘index’’ patients in cohorts of either snap frozen or paraffin
embedded BE and EAC tissues, In the case of the 4q21
chemokine cluster, we extended the validation one-step further,
using serum samples to confirm significantly elevated circulating
levels of two of the cytokines in EAC patients compared to
controls. Notably, other chemokine ligands not included within
the 4q21 amplicon failed to demonstrate any significant
differences between cancer and control specimens, reiterating
the biological relevance of the in silico MIGHT data. Chemokine
ligands have recently been shown to be secreted by malignant
cells and have been shown to participate in neoplastic progression
of melanoma, breast, cervical and colorectal cancers [36-38].
CXCL1, CXCL3 and IL-8 bind to the CXCR2 receptor that has
important roles in oncogene-induced senescence. It has been
suggested that these chemokines potentiate tumor progression
especially with cells with p53 inactivation, an event seen
commonly in esophageal neoplasms [39]. These chemokines
have also been implicated in tumor associated angiogenesis [37]
and are a part of growing evidence of inflammatory mediators
implicated in tumor growth and progression [40]. Our data
reveals mechanisms associated with their upregulation in EAC
and also demonstrates that this upregulation may occur early
during neoplastic transformation, potentially allowing the devel-
opment of a serum-based assay to screen subjects with BE for
neoplastic progression.
Overall, our studies suggest that widespread changes in DNA
methylation, especially hypomethylation, as well as genomic copy
number alterations, can occur early during the multistep process of
esophageal carcinogenesis, and may act in concert to deregulate




Specimens were obtained from patients who underwent
endoscopic surveillance. All patients were diagnosed with Barrett’s
esophagus. After signed informed consent approved by the Johns
Hopkins University IRB, endoscopic biopsies were collected and
snap frozen in liquid Nitrogen, de-linked from direct patient
identifiers and stored at 280 uC. DNA and RNA was extracted
from the same biopsy samples.
Tissue microarray
All specimens were obtained from the surgical pathology files of
the Johns Hopkins Hospital, Memorial Sloan-Kettering Cancer
Center and Karmanos Cancer Center. Tissue microarrays (TMA)
were generated from formalin-fixed paraffin-embedded archival
tissues from 92 patients with Barrett’s Esophagus and included
esophageal squamous epithelium (60 cases), low-grade and high-
grade dysplasia (19 and 38 cases), and adenocarcinoma (80 cases).
Four 1.8 mm tissue cores represented each case and included two
cores from the neoplastic compartment in order to account for
potential tumor heterogeneity, and two cores from adjacent
normal esophageal parenchyma as an internal control.
Additionally for GATA6 IHC, 120 endoscopic mucosal
resection (EMR) specimens from 67 patients with BE were
analyzed, including 31 cases of low grade dysplasia, 40 cases of
high grade dysplasia and 10 cases of adenocarcinoma. All
specimens were obtained from the surgical pathology files of the
Johns Hopkins Hospital.
Figure 6. GATA6 is amplified and functions as an oncogene in esophageal adenocarcinoma. In an index patient with serial progression
biopsies, aCGH shows a progressive copy number gain on the region 18q11.1-q11.2 from normal to dysplasia to cancer. (Panel A). Integrative
approach demonstrates GATA6 and LAMA3 as two genes contained on this cluster (from 17–23,000,000 bp windows) with the marked upregulation
during transformation of normal to dysplasia as well as from dysplasia to cancer. qRT-PCR (red bar) validates the findings on the GE array (blue bar)
and also correlates with the increasing copy number doses seen in the aCGH. No relevant change is detected by the HELP assay (green bar), showing
persistence of unmethylated HpaII sites on the promoter region. GATA6 amplification was corroborated by FISH in the primary adenocarcinoma tissue
from this patient (panel B), RP11-18K7 spectrumOrange represent the 18q11.1-q11.2 region containing the GATA6 gene (red arrows). qRT-PCR on
independent frozen primary tissues demonstrates high detectable mRNA levels in dysplasia and cancer (Mean +/2 SEM). Immunohistochemical
analysis on large number of primary tissues demonstrates elevated protein levels arising as early as in the LGD group. Percentage frequency of
combined results from TMA and EMR are shown (Panel D) and examples of high IHC scores are shown (Panel F-I). To test the functional role of GATA6
upregulation, its expression was characterized in Barrett’s associated adenocarcinoma cell lines (Panel J). Stable knock down of GATA6 from five
shRNAs were screened by qRT-PCR in OE33 cell line (Panel K). shRNA-3 was selected for further experiments. Although there is no effect on cell
viability (panel L), GATA6 loss significantly decreases cell migration (Panel M), Invasion (Panel N) and anchorage independent growth (panel O-P).
doi:10.1371/journal.pgen.1001356.g006
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Rabbit polyclonal GATA6 (H-92) antibody (Santa Cruz Inc, sc-
9055) was used at 1:500 dilution and visualized using the
PowerVision+ Poly-HRP IHC kit (Immunovision Technologies)
following the standard protocol for immunohistochemistry (IHC)
described previously [41]. Immunohistochemical labeling was
assessed in an outcome-blinded fashion by two of the authors
(J.C.R and A.M) on a compound microscope. Intensity of labeling
was evaluated as previously published [42,43].
FISH analysis
The UCSC genome browser was used to select for the BAC
clones spanning the 18q11.2 region: RP11-18K7 (GATA6,
SpectrumOrange); and RP11-49H23 (18q22.2, Control Spec-
trumGreen). For the CXCL1-3 gene cluster, BAC clones covering
the 4q21.1 - 4q21.2 region were RP11-94K4 (SpectrumOrange)
and RP11-259E13 (4q11-q12, Control SpectrumGreen). The
BAC clones were obtained from the Children’s Hospital Oakland
Research Institute in Oakland, USA. We also used commercial
LSI p16/CEP probes (Vysis) for spanning the genetic loci for p16
and p15 (SpectrumOrange) and the alpha satellite sequences
specific to chromosome 9 (SpectrumGreen).
Cell lines and culture conditions
Barrett’s associated adenocarcinoma cell lines OE33 (European
Collection of Cell Cultures, Wiltshire, UK) and JH-EsoAd1,
recently described by our group [44], were maintained in RPMI-
1640 and supplemented with 10% or 20% FBS respectively and
100 U/mL penicillin, 100 mg/mL streptomycin.
Lentiviral shRNA knockdown of GATA6 in OE33 cells
GATA6-expressing OE33 cells were seeded into 24-well plates
at 96104 cells per well concentration, and infected with either
scrambled pLKO.1 (18 bp stuffer) lentiviral vector or with
lentivirus expressing GATA6 shRNA (Open Biosystems, Hunts-
ville, AL). Stable clones were selected by adding 5 mg/ml of
puromycin to the cell culture media. Quantitative reverse
transcription PCR (qRT-PCR) analysis was used to select the
best short hairpin constructs for GATA6 mRNA knockdown.
Downstream experiments were performed with GATA6_sh3 and
compared with scrambled control.
Quantitative reverse transcription PCR (qRT–PCR)
One microgram of total RNA, isolated with the RNAgents kit
(Promega, Madison, WI), were reversed transcribed by using the
Superscript II First Strand kit (Invitrogen) as per manufacturer’s
protocol. 1 mL of cDNA was amplified in a 25 ml volume
containing 12.5 mLo f2 6SYBRGreen PCR Master Mix (Applied
Biosystems) and 0.5 mM of each primer. Reactions were
performed in triplicate using a 7300 Real Time PCR machine
(Applied Biosystems, CA, USA) using PCR conditions and data
analysis as described earlier[41]. The melting curve was
constructed for each primer to ensure reaction specificity.
Following PCR, the threshold cycle (CT) was obtained and
relative quantities were determined by normalization with the
housekeeping gene SDHA.
Statistical analysis
Data are presented as mean and S.E.M. and were compared
using a Student’s t-test (or Mann-Whitney U-test, as appropriate).
A five-parameter logistic equation was used to calculate the curve
fit in the non-linear asymmetric regression. Calculations were
done with Graphpad Prims 4.0.
In vitro cell viability assays
Cell viability assays using the The CellTiter 96AQueousOne
Solution Cell Proliferation Assay (Promega, Madison, WI) were
performed on control-transfected and shRNA-expressing OE33
cells, as described previously [42]. At each time point evaluation,
20 ml/well of the Cell Titer 96 solution was added and incubated
for 1 hour. Plates were read on a Wallac-1420 Plate reader at OD
of 490 nm (PerkinElmer, Boston, MA). All experiments were set
up in triplicate to determine means and standard deviations.
Boyden chamber migration- and invasion assay
The Boyden chamber migration- and invasion assays were
carried out on OE33 cells. For the invasion assay, 56104 cells
were suspended in medium containing 0.2% FBS and plated in the
inner chamber of a matrigel-coated 8-mm polypropylene filter
inserts (BD Matrigel Matrix, BD Falcon). The bottom chamber
contained normal growth media. After 24 h, the cells remaining in
the insert were removed with a cotton swab, and the cells on the
bottom of the filter were fixed and migrated cells were counted
under the microscope. All experiments were set up in triplicate.
Boyden chamber migration assay was carried out following the
procedure described for the invasion assay except that the cells
were plated on uncoated 8-mm pore polypropylene filter inserts in
the Boyden chambers.
Anchorage-independent growth in soft agar
Anchorage-independent growth was assessed by colony
formation assays in soft-agar, as previously described [41].
Briefly, the soft agar assays were set up in 6-well plates, each
well containing a bottom layer of 1% agarose (Invitrogen),
a middle layer of 0.7% agarose including 56103 cells and a top
layer comprising of medium only. Subsequently, the plates were
kept in a tissue culture incubator maintained at 37uCa n d5 %C O
for 14 days to allow for colony growth, with top medium being
changed on a weekly basis. The assay was terminated at day 14,
when plates were stained with 0.005% crystal violet (Sigma-
Aldrich) solution. Colony counting was performed for each
triplicate condition using an automated ChemiDoc XRS instru-
ment (Bio-Rad, Hercules, CA).
Global Gene expression profiling (GE)
Total RNA, was isolated using the RNAgents kit (Promega,
Madison, WI) as per the manufacturer’s instructions and RNA
integrity was corroborated with the Bioanalizer 2100. One
microgram of RNA was reverse transcribed as published
previously [9] and cDNA was submitted to Roche NimbleGen
Systems, Inc. (Madison, WI) for labeling and hybridization onto
the NimbleGen array (2006-10-26_Human_60mer_1in2) con-
taining at least 10 (60mer) probes designed for 37,364 genes
from GenBank build 35. Arrays were scanned using a GenePix
4000B scanner (Axon Instruments) and microarray quality
controls were done as previously described [9]. Gene expression
microarray data will be submitted to the GEO database for
public access. Raw data reports (.pair files) were combined and
analyzed with the RMA 7 (Robust Multi-array Analysis)
package from NimbleScan 2.3 software, including the algo-
rithm for background correction (data based background
correction) and normalization (quantile normalization). After
analysis, results of 36,846 unique nimblegene probes are
reported as log2 values. Accession numbers from which
NimbleGen probes were designed were linked to GenBank
accessions from where Entrez IDs and additional annotations
were isolated.
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The HELP assay was performed as published previously[23,24],
in summary, genomic DNA was isolated from cell lysates (0.1 M
Tris-HCL pH 8.0; 10 mM EDTA pH 8.0 and 1% SDS), digested
overnight at 50C on Proteinase K, follow by several organic
extractions (TE-saturated phenol and Phenol-Chloroform-Isoamyl
alcohol), DNA was purified and concentrated by ethanol
precipitation and resuspended in LOTE pH 7.5 (3 mM Tris-Hcl
and 0.2 mM EDTA). Intact DNA of high molecular weight was
corroborated, by electrophoresis on 1% agarose gel, in all cases.
DNA was digested with the restriction enzyme HpaII (methyla-
tion-sensitive) and MspI (methylation insensitive). Adapters are
ligated to the fragments created by digestion that are subsequently
used for ligation-mediated PCR amplification. The two digestion
products are differentially labeled with two fluorophores and
submitted to Roche NimbleGen Systems, Inc. (Madison, WI) for
hybridization onto a human HG17 custom-designed oligonucle-
otide array (2006-10-26_HG17_HELP_Promoter). The focused
array design stand for 25,626 HpaII-amplifiable fragments (HAF)
defined by those fragments where two HpaII sites are located 200–
2000 bp apart with at least some unique sequence between them
and selected those located at gene promoters and imprinted
regions. Each HAF was represented on the microarray by at least
14 oligonucleotides, each 50 nucleotides in length and randomly
distributed across the microarray slide. HELP microarray data will
be submitted to the GEO database for public access. Raw data
reports (.pair files) went through an analytical pipeline of array
performance and quality assessment previously described [45]. 10
and included removal of failed probes, summarization of the
remaining probes belonging to the 20%-trimmed mean for each
HAF. The functions in this pipeline also allows for quantile
normalization that solves the fragment size-dependency of the
MspI, HpaII and HpaII/MspI ratio distributions seen in this
assay. The R statistical package (http: //www.r-project.org/) was
used to calculate the normalized log2 HpaII/MspI ratios allowing
us to semi-quantitatively categorize each loci as methylated or
hypomethylated based quantitative methylation detected using
MassArray Epityping as a validation approach described below. In
all instances, HpaII-amplifiable fragments (HAF) sequence were
linked to gene promoters (defined as 2000 bp upstream from
transcription start site) by using genomic coordinates from
National Center for Biotechnology Information Build 35.
Array Comparative genomic hybridization (aCGH)
DNA was hybridized to a oligonucleotide array CGH
(NimbleGen Systems), consisting of 388,560 isothermal probes
(length 45–75 bp) covering unique genomic regions (median probe
spacing of 6 kb). Hybridizations were performed at NimbleGen
Facility and a reference sample of Human Male Genomic DNA
was used as a normal control. Intensity data underwent through
a qspline fit normalization algorithm 11 that was used to
compensate for inherent differences in signal between the two
dyes. To avoid false positive calls due to local variation in signal
intensity, a second pass filter was employed. This filter discards
change points if their means are not at least 1.5 SD from each
other. Log2-ratio values of the probe signal intensities (Cy3/Cy5)
were calculated and 120,000 bp windows-average were generated
to visualize copy number changes using the circular binary
segmentation algorithm 12 contained on the Roche NimbleScan
software. Oligonucleotide array data will be submitted to the GEO
database for public access. In all instances, DNA sequence
coordinates are from National Center for Biotechnology Informa-
tion Build 35.
Data integration and 3D visualization
An analytical pipeline was developed to integrate all
platforms. In summary, Gene expression (GE), HELP and
aCGH probes were linked to genes base on the basis of genomic
coordinates isolated from NCBI build35. Probe to gene links
containing data from all three platforms, after proper normal-
ization described above, were considered for 3D integration.
TTEST pairwise comparisons of GE and HELP were
performed between main histological groups (squamous vs
dysplasia and dysplasia vs adenocarcinoma) and fold change
differences with their p-values were calculated. The last two
variables for each pairwise were plotted simultaneously for each
gene on a k-space where the x axis represents fold-change
differences (log2) in GE and the y axis represents fold-change
differences (log2) in methylation. The ‘‘z’’ axis is used to
represent the significance level in –log10 p-value for both
platforms. Color-coding for significant cut-offs was defined for
those genes over 2.5 fold change in GE with a p-value , 0.05,
with green representing downregulated and red upregulated
genes. The same criterion was used to detect significant changes
in methylation. A darker shade of color was added to the red
and green labels to define the hypermethylated genes (on top of
the graph) and lighter shade of red and green was used to define
significantly hypomethylated genes.
Copy number alterations were defined by two fold criteria: the
gene center approach and the genomic segmentation approach. In
the gene center approach, the aCGH probes contained in the
intragenic region or promoter region (when intergenic area was
not available), were averaged. Computational based approach to
find accumulative changes on 50% of DNA content in all three
histological stages for each patient was considered gain or loss
depending if the progressive trend was positive or negative
respectively. A similar approach was also taken for the Circular
binary segmentation (CBS) analysis, this time visual inspection at
genomic windows of 120,000 bp was applied and genomic
segments isolated and classified as gain or losses. Genomic
windows were linked to genes and gene copy number changes
for each patient was defined as those that agreed on last two
criteria. Finally, on the integrative figure, copy number changes
were depicted by larger circles. Genes classified as amplified and
deleted had a 3 fold more larger size compared to their normal
counterparts.
Quantitative DNA methylation analysis by MassArray
Epityping
Quantitative high-throughput DNA methylation analysis to
validate HELP results was carried out by MALDI-TOF mass
spectrometry using Sequenom’s EpiTYPER platform (Sequenom.
San Diego, CA). The same DNA aliquots used for HELP were
bisulfite-converted; PCR amplified and follow by an in vitro RNA
transcription and a base specific cleavage. MALDI TOF MS
analysis of the cleavage product was performed as described
originally [24,25]. MassArray primers were designed and are
available upon request.
Chemokine and cytokine detection
Five serum samples from patients with gastroesophageal reflux
disease (GERD) symptoms and normal esophageal histology, and
five serum samples from esophageal adenocarcinoma patients
were collected for analysis. Frozen endoscopic tissues from the
same patients were also collected and used for tissue lysates. To
determine cytokine levels in the serum, Meso Scale Discovery
System multiplex assay were used for human Eotaxin (CCL11),
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(CCL13) according to the manufacturer’s instructions.
Luminometric methylation assay (LUMA)
Genomic DNA (200–500 ng) was cleaved with HpaII + EcoRI
or MspI + EcoRI in two separate 20 ml reactions containing
33 mM Tris-acetate, 10 mM Mg-acetate, 66 mM K-acetate pH
7.9, 0.1 mg/ml BSA and 5 units of each restriction enzymes. The
reactions were set up in a 96-well format and incubated at 37uC
for 4 h. Then 20 ml annealing buffer (20 mM Tris-acetate, 2 mM
Mg-acetate pH 7.6) was added to the cleavage reactions, and
samples were placed in a PSQ96
TMMA system (Biotage AB,
Uppsala, Sweden). The instrument was programmed to add
dNTPs in four consecutive steps including Step 1: dATP (the
derivative dATPaS is used since it will not react directly with
Luciferase and prevents non-specific signals); Step 2: mixture of
dGTP + dCTP; Step 3: dTTP; and Step 4: mixture of dGTP +
dCTP. Peak heights were calculated using the PSQ96
TMMA
software. The HpaII/EcoRI and MspI/EcoRI ratios were
calculated as (dGTP + dCTP)/dATP for the respective reactions.
The HpaII/MspI ratio was defined as (HpaII/EcoRI)/(MspI/
EcoRI) [46].
Supporting Information
Figure S1 Location of Esophageal Samples: Endoscopic biopsies
from 3 patients (depicted with different colors) were taken. Green
circles represent a 87 yr old male, Blue circles represent a 77 yr old
male and Orange circle represent a 56 yr old female. N=Normal
esophagus; B=Barrett’s esophagus; L=LGD, H=HGD; A=Ad-
enocarcinoma.
Found at: doi:10.1371/journal.pgen.1001356.s001 (0.10 MB
DOC)
Figure S2 Methylation data obtained from the HELP assay
correlates with MassArray Epityper analysis.
Found at: doi:10.1371/journal.pgen.1001356.s002 (0.19 MB
DOC)
Figure S3 Schematic representation of combined effects of
genetic and epigenetic events in esophageal: The first panel shows
that uniallelic genetic deletion of the chr9p21 locus in dysplasia
results in downregulation of both CDKN2A/p16 and CDKN2B/
p15 genes. The reduction in expression though is much greater for
p15 as the promoter gets hypermethylated. The second panel
shows that in addition to amplification, the CXCL1 and CXCL3
gene promoters were also hypomethylated during transformation,
and their relative increase in transcript expression was many fold
greater (4–6 fold by array, 10–20 fold by qRT-PCR) than that of
IL-8, a chemokine gene which was part of the 4q21 amplicon but
whose promoter was not affected by loss of methylation.
Found at: doi:10.1371/journal.pgen.1001356.s003 (0.05 MB
DOC)
Table S1 Genes overexpressed and amplified during transfor-
mation of normal esophageal squamous epithelium to Barrett’s
esophagus and low grade dysplasia.
Found at: doi:10.1371/journal.pgen.1001356.s004 (0.14 MB
DOC)
Table S2 Genes overexpressed and hypomethylated during
transformation of normal esophageal squamous epithelium to
Barett’s esophagus and low grade dysplasia.
Found at: doi:10.1371/journal.pgen.1001356.s005 (0.13 MB
DOC)
Table S3 Genes overexpressed, amplified and hypomethylated
during transformation of normal esophageal squamous epithelium
to Barett’s esophagus and low grade dysplasia.
Found at: doi:10.1371/journal.pgen.1001356.s006 (0.04 MB
DOC)
Table S4 Genes significantly hypomethylated during transfor-
mation with methylation changes occurring outside of CpG
islands.
Found at: doi:10.1371/journal.pgen.1001356.s007 (0.09 MB
DOC)
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